<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23739690</article-id>
      <article-id pub-id-type="pmc">3750905</article-id>
      <article-id pub-id-type="doi">10.1590/S0365-05962013000200027</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Syndrome in Question</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Do you know this syndrome?<xref ref-type="fn" rid="fn01"><sup>*</sup></xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Voc&#xEA; conhece esta s&#xED;ndrome?</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Gontijo</surname>
            <given-names>Gabriela Maria Abreu</given-names>
          </name>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <aff>MD, Dermatologist - Private Clinic - Belo Horizonte - (MG), Brazil </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Gabriela Maria Abreu Gontijo - Rua Jo&#xE3;o Ant&#xF4;nio
Cardoso, 152 - Ouro Preto - 31310-390. Belo Horizonte, MG. - Brazil - E-mail:
<email>gabrielagontijo@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Mar-Apr</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>2</issue>
      <fpage>303</fpage>
      <lpage>305</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>2</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>31</day>
          <month>5</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The Bourneville-Pringle syndrome is an autosomal dominant neurocutaneous disorder
characterized by the development of multiple hamartomas in various systems,
especially brain, skin, retina, kidney, heart and lung. The case of a patient with
brownish plaques on the forehead and temporal region, pink malar and chin papules,
and hypopigmented macules on the back and trunk is described. The diagnosis of the
Bourneville-Pringle syndrome is based on clinical criteria. Presence of two major
criteria, such as facial angiofibromas, forehead fibrous plaques, three or more
hypomelanotic macules establish the definitive diagnosis. The diagnosis should be
made as early as possible in order to assess and treat the associated complications.
</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>A S&#xED;ndrome de Bourneville-Pringle &#xE9; desordem neurocut&#xE2;nea autoss&#xF4;mica dominante
caracterizada pelo desenvolvimento de hamartomas m&#xFA;ltiplos em v&#xE1;rios locais do corpo,
especialmente c&#xE9;rebro, pele, retina, rim, cora&#xE7;&#xE3;o e pulm&#xE3;o. Descreve-se caso de
paciente com placas acastanhadas na fronte e regi&#xE3;o temporal, p&#xE1;pulas r&#xF3;seas na
regi&#xE3;o malar e mento e m&#xE1;culas hipocr&#xF4;micas no dorso e tronco. O diagn&#xF3;stico da
s&#xED;ndrome Bourneville-Pringle &#xE9; baseado em crit&#xE9;rios cl&#xED;nicos. Presen&#xE7;a de dois
crit&#xE9;rios maiores, como angiofibromas faciais, placas fibrosas frontais e 3 ou mais
m&#xE1;culas hipomelan&#xF3;ticas estabelecem o diagn&#xF3;stico definitivo. Devese fazer o
diagn&#xF3;stico o mais precocemente poss&#xED;vel para que as complica&#xE7;&#xF5;es associadas sejam
avaliadas e tratadas. </p>
      </trans-abstract>
      <kwd-group>
        <kwd>Angiofibroma</kwd>
        <kwd>Hamartoma</kwd>
        <kwd>Tuberous sclerosis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>CASE REPORT</title>
      <p>The case of a 13-year-old female patient is here described. Frontal and temporal lesions
appeared at 4 years of age, followed by smaller malar and chin lesions since age 5. Her
mother referred hypochromic maculae on dorsum present from birth. In childhood, she had
one episode of seizure associated with fever, with normal EEG. There was no family
history of similar skin lesions. </p>
      <p>In CT of the skull, multiple amorphous subependimary calcifications were present. In
thoracic and lumbar spine CT, partial defect in fusion of the posterior neural arch was
found at the T11, T12, S1 and L5 levels. </p>
      <p>On examination, she had multiple pinkish-brown, shiny papules, about 2 mm in diameter in
the malar region and chin, brownish frontal and pre-auricular plaques and multiple
hypochromic stains on the trunk, including ash leaf spots (<xref ref-type="fig" rid="f01">Figures 1</xref>,<xref ref-type="fig" rid="f02">2</xref> and <xref ref-type="fig" rid="f03">3</xref>). The frontal and pre-auricular lesions are
probably fibrous plaques, classified as angiofibromas; the patient did not allow a
biopsy, so other possible diagnosis such as melanocytic naevi, verrucous naevi and even
Shagreen patch with unusual localization should be considered. </p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Multiple pinkish-brown shiny papules, about 2 mm in diameter in the malar
region</p>
        </caption>
        <graphic xlink:href="abd-88-0303-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Brownish pre-auricular plaque</p>
        </caption>
        <graphic xlink:href="abd-88-0303-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Ash leaf spot</p>
        </caption>
        <graphic xlink:href="abd-88-0303-g03"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The Bourneville-Pringle syndrome (Tuberous Sclerosis) is an autosomal dominant
neurocutaneous disorder. Two thirds of cases are caused by sporadic mutations; the
incidence is 1:6800-10000 people.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref></sup> It is
characterized by the development of multiple hamartomas in various systems, especially
brain, skin, retina, kidney, heart and lung.<sup><xref ref-type="bibr" rid="r01">1</xref></sup>
</p>
      <p>Two tumor suppressor genes are responsible for the syndrome, TSC1 and TSC2, which encode
the hamartin and tuberin proteins.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref>.<xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r04">4</xref></sup> The hamartin/tuberin complex is an important inhibitor of
tumor growth; its absence triggers the loss of proliferation and cell migration
inhibition.<sup><xref ref-type="bibr" rid="r04">4</xref></sup>
</p>
      <p>As diagnosis is mainly based on clinical criteria, it may be particularly difficult
early in life, since many stigmas become apparent only in late childhood or adulthood. </p>
      <p>The consensus of Tuberous Sclerosis Complex defines that the presence of two major
criteria or one major and two minor criteria establish the definitive diagnosis of the
syndrome.<sup><xref ref-type="bibr" rid="r03">3</xref></sup> The major features
are:<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup>
</p>
      <p>
<list list-type="bullet"><list-item><p>Facial angiofibromas or forehead plaque</p></list-item><list-item><p>Nontraumatic ungual or periungual fibroma</p></list-item><list-item><p>Hypomelanotic macule</p></list-item><list-item><p>Shagreen patch</p></list-item><list-item><p>Multiple retinal nodular hamartomas</p></list-item><list-item><p>Cortical tuber</p></list-item><list-item><p>Subependymal nodule</p></list-item><list-item><p>Subependymal giant cell astrocytoma</p></list-item><list-item><p>Cardiac rhabdomyoma</p></list-item><list-item><p>Lymphangiomyomatosis</p></list-item><list-item><p>Renal angiomyolipoma</p></list-item></list>
</p>
      <p>Minor features are:</p>
      <p>
<list list-type="bullet"><list-item><p>Multiple, randomly distributed pits in dental enamel</p></list-item><list-item><p>Hamartomatous rectal polyps</p></list-item><list-item><p>Bone cysts</p></list-item><list-item><p>Cerebral white matter radial migration lines</p></list-item><list-item><p>Gingival fibromas</p></list-item><list-item><p>Nonrenal hamartomas</p></list-item><list-item><p>Retinal achromic patch</p></list-item><list-item><p>"Confetti" skin lesions</p></list-item><list-item><p>Multiple renal cysts</p></list-item></list>
</p>
      <p>The most important skin lesions are:<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r05">5</xref></sup>
</p>
      <p>
<list list-type="bullet"><list-item><p>Hypomelanotic maculae: the earliest cutaneous lesions, present at birth or
infancy. The most characteristic hypochromic spots are those which have the
form of leaves, called "ash-leaf spots".<sup><xref ref-type="bibr" rid="r04">4</xref></sup>
</p></list-item><list-item><p>Facial angiofibromas: apparent between the second and fifth year of life. Can
be treated by cryosurgery, dermabrasion, curettage, peelings, laser or high
radiofrequency.<sup><xref ref-type="bibr" rid="r06">6</xref></sup> Recent studies described good results with
topical rapamycin, that was also efficient in the treatment of hypomelanotic
maculae.<sup><xref ref-type="bibr" rid="r07">7</xref>,<xref ref-type="bibr" rid="r08">8</xref></sup>
</p></list-item><list-item><p>Shagreen patches: yellowish or erythematous plaques on dorsal body surface,
which are connective tissue nevi.</p></list-item><list-item><p>Forehead fibrous plaques: yellowish-brown, located on the forehead or scalp.
They appear at any age and may be seen at birth.</p></list-item><list-item><p>Periungual fibromas</p></list-item><list-item><p>"Confetti-like" macules</p></list-item></list>
</p>
      <p>Patients also have other manifestations such as dental pits, retinal hamartomas, renal
angiomyolipoma, cardiac rhabdomyomas, cerebral hamartomas, epilepsy, and cognitive
impairment.<sup><xref ref-type="bibr" rid="r01">1</xref>.<xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <p>The diagnosis should be made as early as possible so that the associated complications
may be evaluated and treated. </p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <p>* Study carried out at a Private Clinic - Belo Horizonte (MG), Brazil</p>
      </fn>
      <fn id="fn02" fn-type="financial-disclosure">
        <p>Financial Support: None.</p>
      </fn>
      <fn id="fn03" fn-type="conflict">
        <p>Conflict of Interests: None.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kotulska</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>J&#xF3;zwiak</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Tuberous sclerosis complex: advances in diagnosis, genetics, and
management</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2007</year>
          <volume>57</volume>
          <fpage>189</fpage>
          <lpage>202</lpage>
          <pub-id pub-id-type="pmid">17637444</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borkowska</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Kotulska</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jozwiak</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Tuberous sclerosis complex: tumors and tumorigenesis</article-title>
          <source>Int J Dermatol</source>
          <year>2011</year>
          <volume>50</volume>
          <fpage>13</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">21182496</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curatolo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bombardieri</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jozwiak</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Tuberous sclerosis</article-title>
          <source>Lancet</source>
          <year>2008</year>
          <volume>372</volume>
          <fpage>657</fpage>
          <lpage>668</lpage>
          <pub-id pub-id-type="pmid">18722871</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodrigues</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>IMC</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">Esclerose tuberosa</article-title>
          <source>An Bras Dermatol</source>
          <year>2012</year>
          <volume>87</volume>
          <fpage>185</fpage>
          <lpage>197</lpage>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fern&#xE1;ndez-Guarino</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boixeda</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Anaya</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Beldar</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ja&#xE9;n</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Clinical Findings in 67 Patients With Tuberous
Sclerosis</article-title>
          <source>Actas Dermosifiliogr</source>
          <year>2009</year>
          <volume>100</volume>
          <fpage>596</fpage>
          <lpage>601</lpage>
          <pub-id pub-id-type="pmid">19715644</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gomes</surname>
              <given-names>AAR</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>YVR</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>FB</given-names>
            </name>
            <name>
              <surname>Pessoa</surname>
              <given-names>SGP</given-names>
            </name>
          </person-group>
          <article-title>Multiple facial angiofibromas treated with high-frequency
equipment</article-title>
          <source xml:lang="pt">An Bras Dermatol</source>
          <year>2011</year>
          <volume>86</volume>
          <fpage>S186</fpage>
          <lpage>S189</lpage>
          <pub-id pub-id-type="pmid">22068806</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DeKlotz</surname>
              <given-names>CMC</given-names>
            </name>
            <name>
              <surname>Ogram</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dronavalli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>MacGragor</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Dramatic improvement of facial angiofibromas in tuberous sclerosis
with topical rapamycin: optimizin a treatment protocol</article-title>
          <source>Arch Dermatol</source>
          <year>2011</year>
          <volume>147</volume>
          <fpage>1116</fpage>
          <lpage>1117</lpage>
          <pub-id pub-id-type="pmid">21931059</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wataya-Kaneda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Katayama</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>A novel application of topical rapamycin formulation, an inhibitor of
mTOR, for patients with hypomelanotic macules in tuberous sclerosis
complex</article-title>
          <source>Arch Dermatol</source>
          <year>2012</year>
          <volume>148</volume>
          <fpage>138</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="pmid">22250258</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
